Clinical Trials
8
Active:1
Completed:5
Trial Phases
3 Phases
Phase 1:5
Phase 2:2
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Phase 1
5 (62.5%)Phase 2
2 (25.0%)Phase 3
1 (12.5%)A Phase I, the Study to Evaluate the Safety, Immunogenicity and Efficacy of YS-HBV-002
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Yisheng Biopharma (Singapore) Pte. Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT06162299
- Locations
- 🇵🇭
Iloilo Doctors' Hospital, Iloilo, Philippines
A Study to Evaluate a PIKA Rabies Vaccine（Vero Cell）for Human Use,Freeze-dried
Phase 3
Active, not recruiting
- Conditions
- RabiesPrevention
- First Posted Date
- 2022-12-29
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Yisheng Biopharma (Singapore) Pte. Ltd.
- Target Recruit Count
- 4500
- Registration Number
- NCT05667974
- Locations
- 🇵🇰
Al-Shifa Trust Eye Hospital, Islamabad, Pakistan
🇵🇰Ziauddin University, Karachi, Pakistan
🇵🇰Central Park Teaching Hospital, Lahore, Pakistan
A Phase II/III Study of PIKA Recombinant SARS-CoV-2 Vaccine as a Booster Dose.
Phase 2
Completed
- Conditions
- Covid-19 Vaccine
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Yisheng Biopharma (Singapore) Pte. Ltd.
- Target Recruit Count
- 5860
- Registration Number
- NCT05463419
- Locations
- 🇵🇭
Health Index Multispecialty Clinic -Clinical Research, Cavite, Philippines
🇵🇭Norzel Medical and Diagnostic Clinical, Cebu, Philippines
🇵🇭Tropical Disease Foundation, Muntinlupa, Philippines
A Phase I Study to Evaluate Safety, Tolerability, and Immunogenicity of a PIKA COVID-19 Vaccine in Healthy Individuals
Phase 1
Completed
- Conditions
- COVID-19 Pandemic
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2022-12-22
- Lead Sponsor
- Yisheng Biopharma (Singapore) Pte. Ltd.
- Target Recruit Count
- 135
- Registration Number
- NCT05305300
- Locations
- 🇦🇪
Al Kuwait Hospital (Al Baraha Hospital), Dubai, United Arab Emirates
Dose Escalation and Cohort Expansion Study of YS-ON-001 in Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Cancer
- First Posted Date
- 2017-04-27
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Yisheng Biopharma (Singapore) Pte. Ltd.
- Target Recruit Count
- 31
- Registration Number
- NCT03131765
- Locations
- 🇸🇬
National University Cancer Institute Singapore, Singapore, Singapore
- Prev
- 1
- 2
- Next
News
No news found